Latest Regulatory Risks News

The South Australian Court of Appeal has overturned a 2023 government proclamation, returning the Bird in Hand Gold deposit to Terramin’s exploration licence and reshaping the company’s exploration prospects.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals is seeking a re-examination of the European Medicines Agency’s refusal to approve trofinetide for Rett syndrome, aiming to overturn the setback and bring the treatment to European patients.

ABx Group’s maiden mixed rare earth carbonate from Tasmania’s Deep Leads resource has been confirmed radiologically safe by ANSTO, with a second, higher-grade sample expected soon. The development could open doors to key international customers and reduce regulatory complexities.

Lynas Rare Earths has secured a 10-year renewal of its Malaysian operating licence, providing a significant boost to its investment certainty and supply chain stability.

Steamships Trading Company Limited reported a robust 46% rise in net profit for 2025, driven by strategic investments and operational improvements, while proposing a higher dividend despite ongoing ERP upgrade expenses.

Coles Group reported a 2.5% revenue increase to $23.7 billion for the half year ended January 2026, driven by strong supermarket sales, but earnings were weighed down by a $235 million provision linked to a Fair Work Ombudsman ruling. The company declared a fully franked interim dividend of 41 cents per share.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Foresta Group Holdings reported a 12% increase in its half-year loss to nearly $2 million as it progresses its pioneering wood pellet and pine chemicals project in New Zealand, securing key lease agreements and finalising a $2.4 million insurance settlement.

Firebrick Pharma reports a reduced half-year loss of $1.26 million while launching its Nasodine Throat Spray in Singapore and Fiji, with regulatory approval pending in the Philippines.

Greatland Resources posted a robust half-year profit of $342.9 million, driven by full ownership of the Telfer mine and a strong operational ramp-up. The Havieron feasibility study confirms a world-class gold-copper project, setting the stage for future growth.

Fisher & Paykel Healthcare has raised its full-year revenue and profit forecasts for FY26, buoyed by strong hospital product growth and favourable exchange rates, while navigating the complexities of a recent US Supreme Court tariff ruling.

Newmont Corporation’s 2025 Annual Report reveals a robust financial performance driven by higher gold prices and portfolio optimisation, alongside significant progress in key development projects and sustainability initiatives.